EfficacyHigh
Studies12
Participants450
StatusAvailable
Sermorelin
Sermorelin acetate (GHRH 1-29)
Sermorelin is a synthetic 29-amino acid peptide that mimics the biologically active portion of growth hormone releasing hormone (GHRH). Originally FDA-approved in 1997 as Geref® for treating children with growth hormone deficiency, it stimulates the pituitary gland to produce natural growth hormone in physiological pulsatile patterns. Unlike direct growth hormone injections, sermorelin works with the body's feedback mechanisms to prevent overdose and maintain natural GH rhythms.
Complete Research Database
Clinical Research Outcomes
Clinical Outcome Measures
+18.7
Physical Function
(from 42.3 baseline)
+22.1
Self-Esteem
(from 38.9 baseline)
+15.4
Sexual Life
(from 35.2 baseline)
+24.8
Public Distress
(from 41.7 baseline)
+17.2
Work
(from 44.1 baseline)
Clinical outcome measures
Cardiovascular & Metabolic Outcomes
Blood Pressure Reduction
-6.7 mmHg systolic
Statistical significance: p<0.001
Reduced hypertension medication needs
Triglycerides
-31.5% reduction
Statistical significance: p<0.001
Significant cardiovascular risk improvement
HDL Cholesterol
+8.3% increase
Statistical significance: p<0.01
Improved lipid profile
Waist Circumference
-19.4 cm reduction
Statistical significance: p<0.001
Reduced visceral adiposity
C-Reactive Protein
-41.2% reduction
Statistical significance: p<0.001
Decreased systemic inflammation
Sleep Apnea Events
-58% reduction in AHI
Statistical significance: p<0.001
Improved sleep quality and oxygenation
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.